Eli Lilly & Co. (LLY) the 'Most Attractive Name' in UBS Large Cap Coverage

September 22, 2022 11:35 AM EDT Send to a Friend
UBS analyst Colin Bristow raised Eli Lilly's (NYSE: LLY) rating to Buy from Neutral, with its price target raised to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login